A new study shows that the attention deficit hyperactivity disorder (ADHD) in early pregnancy with stimulants is unlikely to lead to serious birth defects.
The researchers found that amphetamines did not increase the risk, but they found a slight increase in the risk of congenital heart disease in newborns exposed to methylphenidate in early pregnancy. This risk translates into three babies per 1,000 women born with heart defects. However, this one is also statistically significant, which means it seems to be a real risk, but it is very close to accidental discovery.
Krista f. Huybrechts, MS, PhD, Dr Wrote, although the overall risk is very small, but different in measure of ADHD treatment strategies for women of childbearing age and the potential risks and benefits of a pregnant woman, and her colleagues in JAMA Psychiatry.
They noted that women with mild to moderate symptoms of ADHD may stop taking their medication during pregnancy and continue to function without significant difficulty.
They wrote: “if the symptoms are more severe and significant interference in daily function, to continue the medication during pregnancy may be very important, and accidental exposure risk is also high, because there is no plan nearly half of pregnancy.
It is very difficult to study the possible effects of taking different medications during pregnancy, as birth defects have rarely occurred. This means that a study must include a very large number of children to look for small differences in birth defects. In addition, the researchers must also consider the differences between all women who do not take certain medications, which may also play a role in the risk of birth defects. It is impossible to explain every possible factor, so the researchers chose a set of factors that seemed most likely to have an impact on risk.
In this study, the researchers used two large-scale data sets can be analyzed more than 4.3 million records, pregnancy to investigate if there are any birth defects and doping of ADHD medication early pregnancy. They analyzed separately, starting from 2000 to 2013 with more than 1.8 million medical insurance pregnancies in the United States.
Then, the authors conducted a second analysis, attempting to replicate their findings from more than 256 million pregnant data sets from Denmark, Finland, Iceland, Norway and Sweden from 2003 to 2013. These analyses are limited to pregnancies that lead to live births and therefore cannot be used to view miscarriage or stillbirth rates.
Children in the United States, 4.6% of children and 45% of the ritalin contact benzedrine children’s children for some kind of birth defects, and the mother during pregnancy is not taking any kind of drugs with 3.5% of children. Similarly, 1.9% of babies contact ritalin in congenital heart disease, the incidence of amphetamines contact baby was 1.5%, in contrast, 1.3% of babies did not contact the doping in congenital heart disease.
However, the researchers calculated the factors that might affect the outcome, including the various psychiatric and neurological diseases that women may have. The researchers considered other factors include women’s age, race/ethnicity, birth year, the number of children or are to have children, and a variety of health, they are taking other prescription drugs and may come into contact with illegal drugs or drug dependence. Other prescription drugs for women may include medications for diabetes, high blood pressure or other mental health conditions.
After these adjustments for these calculations, the researchers found no congenital heart defects or methylphenidate exposed to increased risk of other defects, these risks are statistically more than chance. Similarly, amphetamines do not increase the risk.
When they analyzed Nordic European data, the author found that the risk of congenital heart disease in the newborn ritalin contact increased by 28%, although this was initially did not reach statistical significance. However, combined with the analysis of American babies, the risk of 28% increase cannot be accidentally ruled out, which is a true finding.
The researchers analyzed the Numbers in several different ways – looking at different subgroups and more on the results of women’s use of drugs and newborns – but the results remained the same.
Heart defects have affected an estimated 1 percent of newborns, or 10 of every 1,000 mothers. The risk of methylphenidate was increased in this study, and three out of every 1,000 mothers were born with congenital heart disease.
Although the study was very large, it improved quality, but it was still based on a single study that looked at historical records. These observational studies are always limited to how much they can tell the researchers. For example, they cannot prove causality and should consider the results of many other similar studies. However, few other studies focus on stimulant drugs during pregnancy, so it takes time to establish sufficient evidence to better understand risk or risk. As usual, when deciding whether to take medication during pregnancy, the mother will have to consider their symptoms and demand, and the benefits of drugs to individual circumstances, as well as to the developing of the potential risk of the baby.